- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04029844
Colibri Transcatheter Aortic Heart Valve System Study
A Prospective, Single Arm Clinical Investigation Evaluating Safety and Performance of the Colibri Transcatheter Aortic Heart Valve System for the Treatment of Symptomatic Severe Aortic Stenosis Via Transfemoral Access in High Surgical Risk Patients
The Colibri Heart Valve clinical investigation ("COL-01") is a prospective, multicenter, exploratory single arm and controlled clinical investigation compared to recent historical results. This study will be conducted in about 7 European sites. The study will evaluate the safety and performance of the Colibri Transcatheter Aortic Heart Valve System for the treatment of symptomatic severe aortic stenosis via transfemoral access in high surgical risk patients.
30 subjects suffering from symptomatic severe aortic tricuspid valve stenosis and who are at high surgical risk (logistic EuroSCORE I > 20% or other risk factors not included in this score such as frailty, porcelain aorta, sequelae of chest radiation or logistic EuroSCORE I < 20% but considered at high risk by local Heart Team evaluation) will be enrolled in this clinical investigation.
The primary objective of this clinical investigation is to evaluate the all-cause mortality at 30 days post implantation. The secondary objectives are to evaluate the safety and performance of the investigational device at 30 days, 6 and 12 months, and 2, 3, 4, 5 years post implantation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: R David Fish, MD
- Phone Number: 1 (303) 460 8667
- Email: colibriTAVI@colibrihv.com
Study Locations
-
-
-
Lille, France
- Recruiting
- Institut Coeur Poumon, CHRU
-
Contact:
- Arnaud Sudre, MD
- Phone Number: 33320445302
-
Massy, France, 91300
- Recruiting
- Hôpital privé Jacques Cartier
-
Contact:
- Thomas Hovasse, Dr
- Phone Number: 33160134602
-
Toulouse, France
- Recruiting
- Clinique Pasteur
-
Contact:
- Didier Tchetche, MD
- Phone Number: 33562211699
-
-
-
-
-
London, United Kingdom, EC1A7E
- Recruiting
- Barts Heart Centre / St Bartholomew's Hospital
-
Contact:
- Andreas Baumbach, MD
- Phone Number: 442037658740
-
-
East Sussex
-
Brighton, East Sussex, United Kingdom, BN2 5BE
- Recruiting
- Brighton & Sussex University Hospital, Roayl Sussex County Hospital
-
Contact:
- David Hildick-Smith, MD
- Phone Number: 64049 44 1273 696955
- Email: david.hildick-smith@bsuh.nhs.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Subject of age > 75 years
- 2. Subject suffering from severe aortic tricuspid valve stenosis defined as follows: High-gradient aortic stenosis (mean pressure gradient across aortic valve > 40 mmHg or peak velocity > 4.0 m/s)
- 3. Subject has symptomatic aortic valve stenosis with New York Heart Association (NYHA) > Class II
- 4. Subject with a documented local Heart Team (HT) agreement of high surgical risk as described in the population
- 5. ECG-gated Multi-Slice Computed Tomographic (MSCT) measurements determined an aortic annulus > 22 mm and < 27.4 mm
- 6. Subject deemed eligible by a TAVI Centralized Case Review Committee (CRC)
- 7. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow-up requirements
Exclusion Criteria:
- 1. Arterial aorto-iliac-femoral axis unsuitable for transfemoral access as assessed by conventional angiography and/or multidetector computed tomographic angiography (access vessel diameter incompatible with a 16F sheath introducer)
- 2. Aortic root anatomy condition or lesion preventing implantation or access to the aortic valve
- 3. Non-calcific acquired aortic stenosis
- 4. Native unicuspid/bicuspid aortic valve or congenital aortic valve abnormality
- 5. Previous implantation of heart valve in any position
- 6. Severe aortic regurgitation (> 3+)
- 7. Severe mitral regurgitation (> 3+)
- 8. Severe tricuspid regurgitation (> 3+)
- 9. Severe left ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF) < 30%)
- 10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- 11. Multi-vessel coronary artery disease (CAD) with a Syntax Score or residual Syntax Score > 22 and/or unprotected left main coronary artery
- 12. Cardiogenic shock
- 13. Untreated cardiac conduction disease in need of pacemaker implantation
- 14. Uncontrolled atrial fibrillation (resting heart rate (HR) > 120bpm)
- 15. Active and/or suspicion of endocarditis or ongoing sepsis
- 16. Blood dyscrasias defined as: leukopenia (White Blood Cells (WBC) < 1,000/mm3), thrombocytopenia (Platelets (PLT) < 50,000/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
- 17. Evidence of acute myocardial infarction (MI) less than 30 days before signing informed consent
- 18. Any need for emergency surgery
- 19. Recent (< 6 months of signing informed consent) CerebroVascular Accident (CVA) or Transient Ischemic Attack (TIA)
- 20. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis < 30 days prior to signing informed consent
- 21. Any active bleeding that precludes anticoagulation
- 22. Liver failure (Child-C)
- 23. End-stage renal disease requiring chronic dialysis or creatinine clearance < 20cc/min
- 24. Pulmonary hypertension (systolic pressure >80mmHg)
- 25. Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by a Forced Expiratory Volume (FEV1) < 750cc
- 26. Refusal of blood transfusion
- 27. A known hypersensitivity or contraindication to all anticoagulation/anti-platelet regimens (or inability to be anticoagulated for the index procedure), to cobalt chromium, to porcine and/or collagen, to glutaraldehyde or contrast media
- 28. Any medical, social or psychological condition that in the opinion of the investigator precludes the subject from giving appropriate consent or adherence to the required follow-up procedures
- 29. Currently participating in another drug or device trial (excluding observational registries) for which the primary endpoint has not been assessed
- 30. Estimated life expectancy of less than 12 months
- 31. For females, pregnancy or intention to become pregnant prior to completion of all follow-up procedures
- 32. Inability to comply with the clinical investigation requirements
- 33. Subject under judicial protection, tutorship or curatorship (for France only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Colibri Device
Treatment
|
Implantation of Colibri heart valve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of all-cause mortality at 30 days post implantation
Time Frame: 30 Days
|
30 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernard Chevalier, MD, Hôpital privé Jacques Cartier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COL-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Aortic Stenosis
-
Yonsei UniversityRecruitingSevere Aortic Stenosis or Severe Aortic RegurgitationKorea, Republic of
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Ceric SàrlEuropean Cardiovascular Research Center; Biosensors InternationalNot yet recruitingAortic Stenosis, Severe
-
Yonsei UniversityRecruiting
-
Edwards LifesciencesRecruiting
-
Edwards LifesciencesCompletedSevere Aortic StenosisSpain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway
-
Second Affiliated Hospital, School of Medicine,...RecruitingSevere Aortic StenosisChina
-
Azienda Usl di BolognaUniversità degli Studi di Ferrara; University Hospital of Ferrara; Azienda Unità...RecruitingAortic Stenosis, SevereItaly
-
Edwards LifesciencesRecruitingAortic Stenosis, SevereUnited States, Australia, New Zealand, Canada
Clinical Trials on Colibri TAVI System
-
Ceric SàrlSymetis SACompletedAortic Valve StenosisGermany, France, Spain, United Kingdom, Denmark, Italy
-
AorticLab SrlMeditrial Europe Ltd.CompletedAortic Valve Stenosis | Intracranial Embolism and ThrombosisItaly, Belgium
-
University of ZurichRecruitingCoronary Artery Disease | Aortic Stenosis | PCI | TAVISwitzerland
-
University Hospital, BonnCompletedAortic Stenosis | Left Ventricular Function Systolic Dysfunction | High-risk Patients | Transcatheter Aortic Valve ImplantationGermany
-
Valve MedicalRecruitingAortic Valve StenosisIsrael
-
University Hospital, MontpellierEdwards LifesciencesCompletedAortic Valve StenosisFrance
-
German Heart InstituteCharite University, Berlin, GermanyUnknownAortic Valve StenosisGermany
-
Institut für Pharmakologie und Präventive MedizinCompletedAortic Valve StenosisCanada, Italy, Netherlands
-
Sheba Medical CenterCompleted
-
JenaValve Technology, Inc.King's College London; Universitätsklinikum Hamburg-EppendorfCompletedAortic Stenosis | Aortic Regurgitation | Aortic InsufficiencyNetherlands, United Kingdom, Switzerland, Germany